Home » Stocks » KYMR

Kymera Therapeutics, Inc. (KYMR)

Stock Price: $39.66 USD 1.00 (2.57%)
Updated Apr 19, 2021 11:59 AM EDT - Market open
Market Cap 1.73B
Revenue (ttm) 34.03M
Net Income (ttm) -45.59M
Shares Out 44.81M
EPS (ttm) -3.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $39.66
Previous Close $38.66
Change ($) 1.00
Change (%) 2.57%
Day's Open 38.37
Day's Range 38.22 - 40.12
Day's Volume 127,527
52-Week Range 25.43 - 91.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models co...

1 week ago - GlobeNewsWire

WATERTOWN, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...

1 week ago - GlobeNewsWire

WATERTOWN, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small mo...

1 month ago - GlobeNewsWire

KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development

1 month ago - GlobeNewsWire

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein d...

1 month ago - GlobeNewsWire

WATERTOWN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein d...

2 months ago - GlobeNewsWire

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...

Other stocks mentioned: ANNX, ASA, BME, BMEZ, BST, BSTZ, GMAB ...
2 months ago - Seeking Alpha

Kymera is one of several biotechs pioneering targeted protein degradation science and technology - removing unwanted proteins by marking them for destruction by the proteasome. The company IPOd in Augus...

3 months ago - Seeking Alpha

WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein d...

3 months ago - GlobeNewsWire

WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein ...

4 months ago - GlobeNewsWire

WATERTOWN, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein ...

4 months ago - GlobeNewsWire

WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that sel...

4 months ago - GlobeNewsWire

WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that sel...

5 months ago - GlobeNewsWire

Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi

5 months ago - GlobeNewsWire

WATERTOWN, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein d...

5 months ago - GlobeNewsWire

Kymera reports positive data for RAK4 degrader, KT-474.

6 months ago - Seeking Alpha

WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule pro...

6 months ago - GlobeNewsWire

Data to be presented at the 5 th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)

6 months ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that ...

7 months ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that ...

7 months ago - GlobeNewsWire

WATERTOWN, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that s...

7 months ago - GlobeNewsWire

WATERTOWN, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that s...

7 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week

Other stocks mentioned: FIIIU, HRMY, NNOX
7 months ago - Seeking Alpha

WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that s...

7 months ago - GlobeNewsWire

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the... [Read more...]

Industry
Biotechnology
IPO Date
Aug 21, 2020
Stock Exchange
NASDAQ
Ticker Symbol
KYMR
Full Company Profile

Financial Performance

In 2020, KYMR's revenue was $34.03 million, an increase of 1,059.99% compared to the previous year's $2.93 million. Losses were -$45.59 million, 10.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is 74.67, which is an increase of 88.30% from the latest price.

Price Target
$74.67
(88.30% upside)
Analyst Consensus: Buy